Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
Status:
Completed
Trial end date:
2021-01-02
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate and compare the single oral dose bioavailability of
Paroxetine manufactured by GlaxoSmithKline (GSK) Pharmaceuticals S.A. for GlaxoSmithKline
México, S.A. de C.V. with that of PAXIL® (Paroxetine) of GlaxoSmithKline, México, S.A. de
C.V. in healthy, adult, male and female participants under fasting conditions. Maximum 38
participants will be randomized and dosed. The expected duration of this study will be 12
days including 7 days of washout period in-between each dosing. PAXIL is a registered
trademark of GSK group of companies.